AU2011317088B2 - Anti-folate receptor alpha antibody glycoforms - Google Patents

Anti-folate receptor alpha antibody glycoforms Download PDF

Info

Publication number
AU2011317088B2
AU2011317088B2 AU2011317088A AU2011317088A AU2011317088B2 AU 2011317088 B2 AU2011317088 B2 AU 2011317088B2 AU 2011317088 A AU2011317088 A AU 2011317088A AU 2011317088 A AU2011317088 A AU 2011317088A AU 2011317088 B2 AU2011317088 B2 AU 2011317088B2
Authority
AU
Australia
Prior art keywords
antibody
fra
fra antibody
cell
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011317088A
Other languages
English (en)
Other versions
AU2011317088A1 (en
Inventor
Luigi Grasso
Wei Gu
Nicholas Nicolaides
Eric Routhier
Philip M. Sass
Jun Yao
Jason Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai Inc
Original Assignee
Eisai Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Inc filed Critical Eisai Inc
Publication of AU2011317088A1 publication Critical patent/AU2011317088A1/en
Application granted granted Critical
Publication of AU2011317088B2 publication Critical patent/AU2011317088B2/en
Priority to AU2016202082A priority Critical patent/AU2016202082A1/en
Assigned to EISAI, INC. reassignment EISAI, INC. Request for Assignment Assignors: MORPHOTEK, INC.
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2011317088A 2010-10-20 2011-10-19 Anti-folate receptor alpha antibody glycoforms Ceased AU2011317088B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2016202082A AU2016202082A1 (en) 2010-10-20 2016-04-04 Anti-Folate Receptor Alpha Antibody Glycoforms

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39481210P 2010-10-20 2010-10-20
US61/394,812 2010-10-20
PCT/US2011/056966 WO2012054654A2 (en) 2010-10-20 2011-10-19 Anti-folate receptor alpha antibody glycoforms

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2016202082A Division AU2016202082A1 (en) 2010-10-20 2016-04-04 Anti-Folate Receptor Alpha Antibody Glycoforms

Publications (2)

Publication Number Publication Date
AU2011317088A1 AU2011317088A1 (en) 2013-05-02
AU2011317088B2 true AU2011317088B2 (en) 2016-01-21

Family

ID=45975873

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2011317088A Ceased AU2011317088B2 (en) 2010-10-20 2011-10-19 Anti-folate receptor alpha antibody glycoforms
AU2016202082A Abandoned AU2016202082A1 (en) 2010-10-20 2016-04-04 Anti-Folate Receptor Alpha Antibody Glycoforms

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2016202082A Abandoned AU2016202082A1 (en) 2010-10-20 2016-04-04 Anti-Folate Receptor Alpha Antibody Glycoforms

Country Status (12)

Country Link
US (1) US20120164137A1 (https=)
EP (1) EP2629798A4 (https=)
JP (1) JP2014505012A (https=)
KR (1) KR20140032944A (https=)
CN (1) CN103347537A (https=)
AU (2) AU2011317088B2 (https=)
BR (1) BR112013009275A2 (https=)
CA (1) CA2815080A1 (https=)
IL (1) IL225579A0 (https=)
MX (1) MX2013004202A (https=)
RU (1) RU2013122843A (https=)
WO (1) WO2012054654A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2607444C (en) * 2005-04-22 2015-03-10 Morphotek, Inc. Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
BR112014028306A2 (pt) 2012-05-15 2018-04-17 Morphotek, Inc. métodos para tratamento de câncer gástrico.
US9200073B2 (en) * 2012-08-31 2015-12-01 Immunogen, Inc. Diagnostic assays and kits for detection of folate receptor 1
US9207238B2 (en) 2012-12-07 2015-12-08 Kyowa Hakko Kirin Co., Ltd. Anti-FOLR1 antibody
US8956830B2 (en) 2013-03-14 2015-02-17 Momenta Pharmaceuticals, Inc. Methods of cell culture
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
US20140271622A1 (en) * 2013-03-14 2014-09-18 Momenta Pharmaceuticals, Inc. Methods of cell culture
US9677105B2 (en) 2013-03-14 2017-06-13 Momenta Pharmaceuticals, Inc. Methods of cell culture
TWI832345B (zh) 2013-03-14 2024-02-11 美商安美基公司 用於增加重組蛋白質之甘露糖含量之方法
CN113150145B (zh) 2013-08-30 2025-02-14 伊缪诺金公司 用于检测叶酸受体1的抗体和测定
EP2871190A1 (en) * 2013-11-11 2015-05-13 ATLAB Pharma Antibody against GD2-O-acetylated ganglioside with pro-apoptotic activity
PT3221356T (pt) 2014-11-20 2020-10-29 Hoffmann La Roche Moléculas de ligação ao antigénio biespecíficas ativadoras das células t contra folr1 e cd3
EP4141032B1 (en) 2014-11-20 2024-05-29 F. Hoffmann-La Roche AG Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists
DK3221357T3 (da) 2014-11-20 2020-08-10 Hoffmann La Roche Fælles letkæder og fremgangsmåder til anvendelse
CA2969225C (en) 2014-12-01 2023-08-22 Amgen Inc. Process for manipulating the level of glycan content of a glycoprotein
CN116440279B (zh) * 2015-09-17 2026-02-24 伊缪诺金公司 包含抗folr1免疫缀合物的治疗组合
AU2019236091B2 (en) 2018-03-13 2025-06-05 Phanes Therapeutics, Inc. Anti-folate receptor 1 antibodies and uses thereof
KR102275930B1 (ko) * 2018-03-14 2021-07-12 (주)알테오젠 Folr1에 특이적으로 결합하는 항체 및 그의 용도
CN118344485B (zh) * 2024-06-18 2024-10-15 南京欧凯生物科技有限公司 抗叶酸及其结合蛋白复合物的单克隆抗体或其抗原结合片段、其制备方法及应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090274697A1 (en) * 2004-02-12 2009-11-05 Luigi Grasso Monoclonal Antibodies That Specifically Block Biological Activity Of A Tumor Antigen
US20090324594A1 (en) * 2005-04-22 2009-12-31 Nicolaides Nicholas C Antibodies With Immune Effector Activity And That Internalize In Folate Receptor Alpha-Positive Cells

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1648511A1 (en) * 2003-07-29 2006-04-26 Morphotek, Inc. Antibodies and methods for generating genetically altered antibodies with enhanced effector function
AU2005274905B2 (en) * 2004-08-04 2010-12-23 Mentrik Biotech, Llc Variant Fc regions
CN101374545B (zh) * 2005-04-15 2012-03-28 免疫基因公司 消除肿瘤中的异质或混合细胞群体
SG153825A1 (en) * 2005-12-16 2009-07-29 Ibc Pharmaceuticals Inc Multivalent immunoglobulin-based bioactive assemblies
WO2011116387A1 (en) * 2010-03-19 2011-09-22 Tetragenetics, Inc. Production of aglycosylated monoclonal antibodies in ciliates

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090274697A1 (en) * 2004-02-12 2009-11-05 Luigi Grasso Monoclonal Antibodies That Specifically Block Biological Activity Of A Tumor Antigen
US20090324594A1 (en) * 2005-04-22 2009-12-31 Nicolaides Nicholas C Antibodies With Immune Effector Activity And That Internalize In Folate Receptor Alpha-Positive Cells

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Abes et al (2010) Pharmaceuticals, 3(1):146-157 *
Hossler et al (2009) Glycobiology, June, 19(3):936-949 *
Jefferis (2005) Biotechology Progress, January, 21(1):11-16 *
Jefferis (2009) Nature Reviews Drug Discovery, March, 8(3):226-234 *

Also Published As

Publication number Publication date
WO2012054654A3 (en) 2012-08-02
IL225579A0 (en) 2013-06-27
AU2011317088A1 (en) 2013-05-02
KR20140032944A (ko) 2014-03-17
EP2629798A4 (en) 2014-05-28
EP2629798A2 (en) 2013-08-28
WO2012054654A2 (en) 2012-04-26
RU2013122843A (ru) 2014-11-27
CA2815080A1 (en) 2012-04-26
AU2016202082A1 (en) 2016-04-28
JP2014505012A (ja) 2014-02-27
CN103347537A (zh) 2013-10-09
MX2013004202A (es) 2013-10-17
US20120164137A1 (en) 2012-06-28
BR112013009275A2 (pt) 2017-06-20

Similar Documents

Publication Publication Date Title
AU2011317088B2 (en) Anti-folate receptor alpha antibody glycoforms
JP6880100B2 (ja) Ｃｄｈ１９およびｃｄ３に対する抗体構築物
CA2940685C (en) Anti-egfrviii antibodies and uses thereof
EP3328888B1 (en) Anti-psma antibodies, bispecific antigen-binding molecules that bind psma and cd3, and uses thereof
TWI907431B (zh) 包含ｃｄ３抗原結合域之蛋白質及其用途
EP3848395A1 (en) Antibody compositions for tumor treatment
JP2021518140A (ja) Ｍｉｃａおよび／またはｍｉｃｂに対する抗体ならびにそれらの使用
JP2021510535A (ja) Ｈｅｒ３抗原結合性分子
EA037882B1 (ru) Агонистические антитела, специфически связывающие человеческий cd40, и способы их применения
US20240002503A1 (en) Novel anti-lilrb2 antibodies and derivative products
KR20230110523A (ko) 델타-유사 리간드 3(dll3) 항원 결합 영역을 포함하는 단백질 및 그의 용도
EP4467571A1 (en) Anti-cd3 and anti-cd20 bispecific antibody and use thereof
CN112424357A (zh) 与硫酸软骨素蛋白聚糖5结合的抗体
CA2767442A1 (en) Antibody having anti-cancer activity
WO2023098785A1 (zh) 抗4-1bb抗体及其用途
US20260028405A1 (en) Anti-cd16a antibodies and methods of use thereof
KR20250130296A (ko) 항-ccr8 항체 및 이의 용도
WO2024163530A2 (en) Novel anti-ccr4 antibodies and derivative products
WO2023143478A1 (en) Novel anti-cd4 and anti-pd-l1 bispecific antibodies
US20250313625A1 (en) Novel anti-lag3 antibodies
WO2012057765A1 (en) Recombinant anti-cd19 monoclonal antibodies
US20240034786A1 (en) An antibody against p-cadherin and uses thereof
TW202523694A (zh) 抗muc16抗體及其用途
AU2024380169A1 (en) Anti-muc16 antibodies and uses thereof
HK40093208A (en) Anti-psma antibodies, bispecific antigen-binding molecules that bind psma and cd3, and uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: EISAI, INC.

Free format text: FORMER OWNER(S): MORPHOTEK, INC.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired